Background: benign prostatic hyperplasia represents one of the main fields of urology. objective: aim of the study to verify the efficacy and safety of the alfa one adrenoreceptor blocker silodosin compared with tamsulosin in patients with lower urinary tract symptoms associated with bph. patients and methods: outcomes were assessed by change from baseline in ipss, quality of life (qol), qmax, pvr. responders to the treatments on the basis of ipss decrease ≥ 25% and qmax increase ≥ 30% were calculated. results: silodosin and tamsulosin significantly improved ipss total score in (p=0.625). both no statistically significant difference. improved qol (p<0.505) both no statistically significant difference between both improved qmax (p<0.633). silodosin and tamsulosin no statistically significantly. improved pvr; there no statistically significant difference between both (p<0.0001). in silodosin group, a retrograde ejaculation was reported in 25 patients from 40 patients were sexually active (62.5%). while in tamsulosin group, a retrograde ejaculation was reported in 1 patient from 41 patients sexually active (2.4%). conclusions: silodosin is not only comparable to tamsulosin in the treatment of luts/bph, with safety. however, retrograde ejaculation troublesome for sexually active patients.